Antiviral drugs for the treatment of viral respiratory tract infections and COVID-19: consensus of experts

REFERENCES

1. World Health Organization. A coordinated global research roadmap: 2019 novel coronavirus. March 2020. https://www.who.int/blueprint/priority-diseases/key-action/Coronavirus_Roadmap_V9.pdf?ua=1 (date of acces: 17.11.2021).

2. Coronavirus spread statistics in Russia. https://coronavirus-monitor.info/country/russia (date of acces: 17.11.2021). (in Russian)

3. Yu C., et al. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: A retrospective matched-pair cohort study. J Med Virol. 2021; 93 (1): 472-80. DOI: https://doi.org/10.1002/jmv.26260

4. Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 13 from 10/14/2021. https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf (date of access: 17.11.2021). (in Russian)

5. Leneva I., et al. Antiviral activity of umifenovir in vitro against a broad spectrum of coronaviruses, including the novel SARS-CoV-2 virus. Viruses. 2021; 13 (8). DOI: https://doi.org/10.3390/v13081665

6. Wang X., et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020; 6 (1): 28. DOI: https://doi.org/10.1038/s41421-020-0169-8

7. Sanders J.M., et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020; 323 (18): 1824-36. DOI: https://doi.org/10.1001/jama.2020.6019

8. Vankadari N. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents. 2020; 56 (2): 105998. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105998

9. Gao W., et al. Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series. Virol J BioMed Central, 2020; 17 (1): 162. DOI: https://doi.org/10.1186/s12985-020-01428-5

10. Zeng H., et al. Antiviral abidol is associated with the reduction of in-hospital mortality in COVID-19 patients // Cardiol. Discov. 2021. Vol. 1, N 1.P. 37-43. DOI: https://doi.org/10.1097/CD9.0000000000000014

11. Pshenichnaya N.Yu., et al. Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020. Terapevticheskii Arkhiv [Therapeutic Archive]. 2021; 93 (11): 1306-15. DOI: https://doi.org/10.26442/00403660.2021.11.201206 (in Russian)

12. Ghaderkhani S., salami Khaneshan A., Salami A., et al. Efficacy and safety of arbidol in treatment of patients with COVID-19 infection: a randomized clinical trial. Res Sq. Published online 2021. DOI: https://doi.org/10.21203/rs.3.rs-91430/v1

13. Nojomi M., et al. Effect of arbidol (umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis BioMed Central. 2020; 20 (1): 954. DOI: https://doi.org/10.1186/s12879-020-05698-w

14. Yang C., et al. Effectiveness of arbidol for COVID-19 prevention in health professionals. Front Public Heal. 2020; 8: 1-6. DOI: https://doi.org/10.3389/fpubh.2020.00249

15. Zhang J., et al. Potential of arbidol for post-exposure prophylaxis of COVID-19 transmission - a preliminary report of a retrospective cohort study. Curr Med Sci. 2020; 40 (3): 480-5. DOI: https://doi.org/10.1007/s11596-020-2203-3.

16. Zhou J., et al. Clinical characteristics of repositive COVID-19 patients in Huangshi, China: A retrospective cohort study. PLoS One. 2020; 15 (11): 1-15. DOI: https://doi.org/10.1371/journal.pone.0241896

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»